EKONOMIAREN GARAPEN
ETA LEHIAKORTASUN SAILA
DEPARTAMENTO DE DESARROLLO
ECONÓMICO Y COMPETITIVIDAD
General overview of the ...
Coopera ve
Research
Centres
1
Health
Research
Ins tutes
3
Technology
Centres
4
Companies
5
Universi es of the
Basque Count...
BASQUE NANOMEDICINE ACTIVITY
IMPACT OF BASQUE NANOMEDICINE ACTIVIY UNDER FP7
Direct impact and uptake into FP7 topics and ...
Coopera ve
Research
Centres
1
CIC nanoGUNE, the Basque
Nanoscience Coopera ve
Research centre, was inaugurated
in 2009 with the mission to
perform world...
NANOMEDICINE RELATED ACTIVITY
Mechanomedicine:
Study of mechanical forces
in human pathologies,viral,
and bacterial infec ...
SELF ASSEMBLY GROUP
Alexander Bi ner, self-assembly group leader
a.bi ner@nanogune.eu
Drug delivery from a plant virus nan...
Understanding Viral and Baceterial
Infec ons using Atomic Force Microscopy
Coopera ve
Research
Centres
1 NANOBIOMECHANICS ...
NANOMAGNETISM GROUP
Paolo Vavassori, nanomagne sm group co-leader
p.vavassori@nanogune.eu
Nano-magne c devices for remote ...
CIC biomaGUNE Centre for
Copera ve Research in biomaterials
is a non-profit research organiza on
created to promote scien fi...
Biomaterialetako Ikerkuntza Kooperatiboko Zentroa
Centro de Investigación Cooperativa en Biomateriales
NANOMEDICINE RELATE...
Uptake, biological fate, and toxicity of metal oxide nanopar cles
Studies of the uptake, biological fate, and toxicity of ...
68
Ga-Labeled Gold Glyconanopar cles for Exploring Blood–Brain
Barrier Permeability: Prepara on, Biodistribu on Studies, a...
Universi es
of the
Basque
Country
2
Synthe c polymers are found in such a
large variety of products that have shaped
modern life. In the future, polymers will...
NANOBIOSEPARATIONS GROUP
NANOMEDICINE RELATED ACTIVITY
DNA-gated nanopar cles for drug
delivery and controlled release
DNA...
DNA-aptamer gated nanopar cles and membranes
for controlled delivery and drug release
Mesoporous nanopar cles and nanoporo...
DNA-modified polymeric interfaces for disease
detec on pla orms
Interfaces are created through DNA-aptamers
being gra ed on...
BIONANOPARTICLES GROUP
NANOMEDICINE RELATED ACTIVITY
Synthesis and characteriza on of
hard, hybrid, and so nanopar cles
fo...
Design of Ca onic Nanogels for Targeted Intracellular
Codelivery of Doxorubicin and siRNA to Overcome
Drug Resistance in B...
SCIENCE AND ENGINEERING OF POLYMERIC BIOMATERIALS GROUP
NANOMEDICINE RELATED ACTIVITY
Novel bioresorbable polymer
systems ...
Novel bioresorbable polymer systems
for regenera ve medicine
Bioresorbable polymers with thermoplas c
elastomer (TPE) beha...
Bioresorbable polymer scaffolds func onalized
with a model protein for local delivery of
an bio cs and immuno-supresive mol...
Since 2001, the research group from the
Pharmacy and Pharmaceu cal Science´s
Deparment has been recognized as a
University...
NANOMEDICINE RELATED ACTIVITY
Microencapsula on of alive cells. Design
and op miza on of polymeric systems for
immobiliza ...
Treatment of re na neurodegenera ves diseases through gene
therapy using non viral vectors
Niosomes represent a recent pro...
Alzheimer treatment through revasculariza on of cerebral cortex
With this development a empts to develop a novel nanotechn...
Health
Research
Ins tutes
3
First health research ins tute in the
Basque Country: Created in 2008
Accredited by the ISCIII: indicator of
excellence, p...
NANOMEDICINE RELATED ACTIVITY
Research on the inmunologic response
in the presence of nanopar cles
Research on the inmunol...
Technology
Centres
4
TECNALIA Research & Innova on
is a private, non-profit research
organiza on that operates in several
markets (Construc on, ...
NANOMEDICINE RELATED ACTIVITY
Synthesis, func onaliza on and
characteriza on of polymeric
nanopar cles for targeted drug d...
New enabling technologies for transdermal
delivery of nanopar cles
Nanopar cles introduced into the skin may
be used for v...
Nanotoxicity assessment
Nanotoxicology is a science that is s ll in its infancy
and there is s ll a major lack of toxicolo...
Fundación GAIKER is a organiza on
devoted to the development of new
technologies from sectors such as
Health, Fine Chemist...
NANOMEDICINE RELATED ACTIVITY
In vitro evalua on of the absorp on
capa city of nanodrugs
ITS for toxicity assessment
of na...
In vitro evalua on of the absorp on
capa city of nanodrugs
Development of models to simulate
physiological barriers in vit...
ITS for toxicity assessment of nanodrugs
An Intelligent Tes ng Strategy has been
designed to screen for the toxicity
poten...
IK4-CIDETEC is a Research
Ins tute specialized in
genera ng and transferring
knowledge and technology
in the areas of mate...
NANOMEDICINE RELATED ACTIVITY
Synthesis of Biomaterials
Polymer NPs for theragnosis
Nanogels, nanocapsules: pH responsive
...
TRL: 4
Time to market: medium/long 3-5 / >5
POLYMER NANOPARTICLES FOR TARGETED
IMAGING AND THERAPY OF CANCER
Mul func onal...
TRL: 4-5
Time to market: short if it is applied as a medical device
HYDROGELS
Injectable hydrogels with self-healing prope...
TRL: 4
Time to market: medium
NANOCAPSULES
Emulsifiers based on amphiphilic diblock copolymers
pH responsive capsules based...
IK4-TEKNIKER (TKN) is a private non-
profit research organisa on. IK4
Tekniker is part of the IK4 Research
Alliance. Micro-...
Technology
Centres
4 NANOMEDICINE RELATED ACTIVITY
Micro and Nanofabrica on Unit
in a Clean-room
In-vitro diagnos c tools ...
Technology
Centres
4
TRL: 4
Time to market: short/medium/long <3 / 3-5 / >5
In-vitro diagnos c by LSPR
System integra on f...
Technology
Centres
4
TRL: 5
Time to market: short/medium/long <3 / 3-5 / >5
In-vitro diagnos c of biomolecules by
electroc...
Technology
Centres
4
TRL: 5
Time to market: short/medium/long <3 / 3-5 / >5
Micro and Nanostructures for cell a achment,
p...
Technology
Centres
4
Vicomtech-IK4 is a non-profit
applied research centre specialised
in Computer Graphics, Visual
Compu n...
Technology
Centres
4 MAIN INFRASTRUCTURES
Vicomtech-IK4 is equipped for
research into new medical image
display techniques...
Technology
Centres
4
TRL: 3
Time to market: 3-5
Image processing solu on for nanosystems’s
development and valida on
Tools...
Companies
5
Biopraxis Research AIE cons tutes
the R&D division of Praxis
Pharmaceu cal Group. Praxis is
a young pharma company, which
...
NANOMEDICINE RELATED ACTIVITY
Nanomedicine is a key pillar for
Biopraxis development strategy.
We have established a capac...
Novel strategy for the treatment of chronic wounds
Lipid nanopar cles are currently receiving increasing
interest because ...
Theranos cs for treatment of glioma
In the framework of the FP7 project Theraglio,
novel systems for theranos cs for gliom...
Innova ve drugs based on nano en es
produced by compressed fluids
This technology, developed by ICMAb-CSIC/
Nanomol and GMP...
Midatech is a world leader in the
design, synthesis and manufacture
of biocompa ble gold nanopar cles
with a core focus on...
NANOMEDICINE RELATED ACTIVITY
Novel par cles with single or
mul ple ac ve pharmaceu cal
ingredients tailored to op mal
the...
METABOLIC DISEASE: DIABETES
Transbuccal insulin
Midatech’s most advanced programme takes
advantage of the fact that bindin...
ONCOLOGY
Midatech is developing a new cancer therapies based on
nanomedicines combining validated chemotherapeu cs,
targe ...
www.nanobasque.eu
nanobasque@spri.es
nanoBasque
EKONOMIAREN GARAPEN
ETA LEHIAKORTASUN SAILA
DEPARTAMENTO DE DESARROLLO
ECO...
of 63

General overview of the latest nanomedicine developments in the Basque Country

Cooperave Research Centres, Universities of the Basque Country UPV/EHU, Health Research Institutes, Technology Centres, Companies
Published on: Mar 3, 2016
Published in: Technology      
Source: www.slideshare.net


Transcripts - General overview of the latest nanomedicine developments in the Basque Country

  • 1. EKONOMIAREN GARAPEN ETA LEHIAKORTASUN SAILA DEPARTAMENTO DE DESARROLLO ECONÓMICO Y COMPETITIVIDAD General overview of the latest nanomedicine developments in the Basque Country
  • 2. Coopera ve Research Centres 1 Health Research Ins tutes 3 Technology Centres 4 Companies 5 Universi es of the Basque Country UPV/EHU 2
  • 3. BASQUE NANOMEDICINE ACTIVITY IMPACT OF BASQUE NANOMEDICINE ACTIVIY UNDER FP7 Direct impact and uptake into FP7 topics and calls All NMP calls included a nanomedicine topic Nanomedicine under FP7: 85 NMP, 31 Health, 15 ICT 15 Basque members in 17 projects under FP7 16 NMP; 1 HEALTH 5 coordinated from Basque Country 12 Million € EC contribu on Basque members at na onal nanomedicine pla orm (NANOMED SPAIN) 20 Basque members at NanoMed Spain University CICs Technology Centres Companies CICs Research Centre Hospital University groups Technology Centres Companies
  • 4. Coopera ve Research Centres 1
  • 5. CIC nanoGUNE, the Basque Nanoscience Coopera ve Research centre, was inaugurated in 2009 with the mission to perform world-class nanoscience research for the compe ve growth of the Basque Country. www.nanogune.eu Coopera ve Research Centres 1
  • 6. NANOMEDICINE RELATED ACTIVITY Mechanomedicine: Study of mechanical forces in human pathologies,viral, and bacterial infec ons Mechanopharmacology Drug delivery: Design of nanopar cles and nanostructures for drug delivery Development of nanomagne c devices for remote manipula on Coopera ve Research Centres 1 MAIN INFRASTRUCTURES Atomic-Force Spectroscopy Magne c Tweezers High-Performance Liquid Chromatography + Mass Spectrometry Environmental SEM SQUID magnetometer Cell-Culture Laboratory Infrared spectromicroscopy Electrospinning CONTACT PERSON Name: Itziar Otegui E-mail: i.otegui@nanogune.eu
  • 7. SELF ASSEMBLY GROUP Alexander Bi ner, self-assembly group leader a.bi ner@nanogune.eu Drug delivery from a plant virus nanotube TRL: 1 Time to market: long Immersion in oxalipla n and dialysis Slow Effusion drug delivery over some days Coopera ve Research Centres 1
  • 8. Understanding Viral and Baceterial Infec ons using Atomic Force Microscopy Coopera ve Research Centres 1 NANOBIOMECHANICS GROUP Raúl Perez Jimenez, nanobiomechanics group leader r.perezjimenez@nanogune.eu
  • 9. NANOMAGNETISM GROUP Paolo Vavassori, nanomagne sm group co-leader p.vavassori@nanogune.eu Nano-magne c devices for remote manipula on of biomolecules and cells Novel device concept for a 2-dimensional remote manipula on of magne c beads along any arbitrary pathway on a chip surface. We realized test devices that proved the remote manipula on of individual and mul ple magne c nano-par cles on a chip surface. Applica ons: lab on a chip, magne c templates for ssues regenera on, in-flow sor ng of biomolecules, and biodetec on. Coopera ve Research Centres 1 TRL: 3 Time to market: 3-5 / >5
  • 10. CIC biomaGUNE Centre for Copera ve Research in biomaterials is a non-profit research organiza on created to promote scien fic research and technological innova on at the highest levels in the Basque Country following the BIOBASQUE policy in order to create a new business sector based on biosciences. www.cicbiomagune.es Biomaterialetako Ikerkuntza Kooperatiboko Zentroa Centro de Investigación Cooperativa en Biomateriales Coopera ve Research Centres 1
  • 11. Biomaterialetako Ikerkuntza Kooperatiboko Zentroa Centro de Investigación Cooperativa en Biomateriales NANOMEDICINE RELATED ACTIVITY Biofunc onal Nanomaterials Biosurfaces Molecular Imaging Coopera ve Research Centres 1 CONTACT PERSON Name: Dr. Luis Liz Marzán E-mail: llizmarzan@biomagune.es MAIN INFRASTRUCTURES Radiochemistry MRI Nuclear Imaging Image Analy cs Animal Facility NMR Electron Microscopy Mass Spectrometry Surface analysis and fabrica on Colloidal Nanofabrica on Op cal Spectroscopy
  • 12. Uptake, biological fate, and toxicity of metal oxide nanopar cles Studies of the uptake, biological fate, and toxicity of several metal oxide nanopar cles (NPs), such as Al2 O3 , TiO2 , CeO2-x , and ZnO NPs undertaken in the European Project “Health Impact of Engineered Metal and Metal Oxide Nanopar cles: Response, Bioimaging and Distribu on at Cellular and Body Level” are reviewed here. Metal oxide NPs are radiolabeled by direct proton bombardment of commercially available NPs or enriched during synthesis with 18 O to generate 18 F a er-proton bombardment. Size, degree of aggrega on, and zeta poten al of the metal oxide NPs are studied in the presence of proteins and cell media. NP uptake and intracellular fate are followed by ion beam microscopy (IBM), transmission electron microscopy, confocal Raman microscopy and confocal laser scanning microscopy. IBM allows for the quan fica on of the intracellular dose of NPs. Cell viability studies and the immune response are studied “in vitro” in primary alveoli, and immortalized cell lines. Biodistribu on studies in rodents are performed with positron emission tomography following different exposure routes: intravenous, oral, topical, and inhala on using radiolabelled NPs. Ac vity per organ is quan fied for the different uptake routes and with the me. TRL: 3 Time to market: long Biomaterialetako Ikerkuntza Kooperatiboko Zentroa Centro de Investigación Cooperativa en Biomateriales Coopera ve Research Centres 1
  • 13. 68 Ga-Labeled Gold Glyconanopar cles for Exploring Blood–Brain Barrier Permeability: Prepara on, Biodistribu on Studies, and Improved Brain Uptake via Neuropep de Conjuga on Synthesis of novel water-soluble and biocompa ble glucose-coated gold nanopar cles (GNPs) carrying BBB-permeable neuropep des and a chelator of the positron emi er 68 Ga as a PET reporter for in vivo tracking biodistribu on. The small GNPs (2 nm) are stabilized and solubilized by a glucose conjugate. A NOTA ligand is the chela ng agent for the 68 Ga, and two related opioid pep des are used as targe ng ligands for improving BBB crossing. The radioac ve labeling of the GNPs is completed in 30 min at 70 °C followed by purifica on via centrifugal filtra on. As a proof of principle, a biodistribu on study in rats is performed for the different 68 Ga-GNPs. The accumula on of radioac vity in different organs a er intravenous administra on is measured by whole body PET imaging and gamma counter measurements of selected organs. The biodistribu on of the 68 Ga-GNPs varies depending on the ligands, as GNPs with the same gold core size show different distribu on profiles. One of the targeted 68 Ga-GNPs improves BBB crossing near 3-fold (0.020 ± 0.0050% ID/g) compared to nontargeted GNPs (0.0073 ± 0.0024% ID/g) as measured by dissec on and ssue coun ng. Biomaterialetako Ikerkuntza Kooperatiboko Zentroa Centro de Investigación Cooperativa en Biomateriales Coopera ve Research Centres 1 TRL: 3 Time to market: long
  • 14. Universi es of the Basque Country 2
  • 15. Synthe c polymers are found in such a large variety of products that have shaped modern life. In the future, polymers will con nue subs tu ng other materials in established applica ons and will play a major role in the development of the technologies needed to address some of the 21st Century challenges such as energy, health care and sustainability. POLYMAT is devoted to use- inspired fundamental research on synthesis, assembly and processing of polymers that in concert with theory and simula on enable addressing to these challenges. www.polymat.eu POLYMAT, University of the Basque Country UPV/EHU Universi es of the Basque Country UPV/EHU 2 CONTACT PERSON Name: Idoia Azaldegui E-mail: idoia.azaldegui@polymat.eu
  • 16. NANOBIOSEPARATIONS GROUP NANOMEDICINE RELATED ACTIVITY DNA-gated nanopar cles for drug delivery and controlled release DNA-modified polymeric interfaces for disease detec on pla orms MAIN INFRASTRUCTURES Surface-sensi ve techniques (SPR, DPI, QCM-D) Polymer processing and characteriza on CONTACT PERSON Name: Prof. Dr.-Ing. Thomas Schäfer E-mail: thomas.schafer@ehu.es Universi es of the Basque Country UPV/EHU 2
  • 17. DNA-aptamer gated nanopar cles and membranes for controlled delivery and drug release Mesoporous nanopar cles and nanoporous membranes are loaded with cargo molecules (such as drugs) and then capped with DNA-aptamers. Upon interac ng with the cognate target, the DNA-aptamer changes conforma on giving rise to an opening of the pores and subsequent release of the cargo. Proof of concept has been succeeded with cancer cells but applica ons might also be in smart biosepara ons. TRL: Time to market: short/medium/long >5 Universi es of the Basque Country UPV/EHU 2
  • 18. DNA-modified polymeric interfaces for disease detec on pla orms Interfaces are created through DNA-aptamers being gra ed on polymeric thin films via suitable surface modifica on. Such interfaces can be used either as selec ve thin films on sensors or as membranes in purifica on technology. Applica ons under preliminary study range from detec on of markers for diseases to ssue engineering. TRL: 2 Time to market: short/medium/long >5 Universi es of the Basque Country UPV/EHU 2
  • 19. BIONANOPARTICLES GROUP NANOMEDICINE RELATED ACTIVITY Synthesis and characteriza on of hard, hybrid, and so nanopar cles for bio-applica ons Colloidal and polymeric characteriza ons of bionanopar cles Modeling the heterogeneous polymeriza on processes to produce hard, hybrid, and so nanopar cles for bio-applica ons In vitro preliminary bio-applica ons using hard, hybrid, and so bionanopar cles Universi es of the Basque Country UPV/EHU 2 MAIN INFRASTRUCTURES 800 m2 of new labs and offices with state-of-the-art equipment for controlled synthesis (computer controlled reactors, RC1 calorimeter reactor, high throughput reactor system) and characteriza on (1 H and 13 C NMRs, AFM, TEM, SEM, FTIR, DSC, GPC, DLS, MALS, CHDF, DCP, MALDI-TOF, tensiometer, contact angle, rheometer) of polymer materials. Also, free access to all the infrastructures of the General Research Services of the UPV/EHU. CONTACT PERSON Name: Jose Ramos E-mail: jose.ramos@ehu.es
  • 20. Design of Ca onic Nanogels for Targeted Intracellular Codelivery of Doxorubicin and siRNA to Overcome Drug Resistance in Breast Cancer Drug resistance to chemotherapy is believed to cause failure in over 90% of pa ents with metasta c cancers. Therefore, to overcome mul drug resistant (MDR) in breast cancer, the main objec ve of this project is the synchronous targeted codelivery of doxorubicin (Dox) as a chemotherapeu c an cancer drug together with a specific small interfering RNA (siRNA) for knocking down a Dox resistance gene, using a folate-conjugated ca onic nanogel able to degrade intracellularly. This project is carried out in collabora on with the group of Prof. Molly Stevens at Imperial College London, and the final stages of this project will be carried out at BioDonos a Health Research Ins tute and Glaxo Smith Kline (GSK) in order to validate and assess the clinical transla on of the product. Universi es of the Basque Country UPV/EHU 2 TRL 3: experimental proof of concept TRL 4: technology validated in lab Time to market: long >5
  • 21. SCIENCE AND ENGINEERING OF POLYMERIC BIOMATERIALS GROUP NANOMEDICINE RELATED ACTIVITY Novel bioresorbable polymer systems for ssue engineering Polymer scaffolds and medical devices with biologically ac ve molecules Synthesis, characteriza on and conforma on of polymeric biomaterials Universi es of the Basque Country UPV/EHU 2 CONTACT PERSON Name: Prof. Dr. Jose-Ramon Sarasua E-mail: jr.sarasua@ehu.es MAIN INFRASTRUCTURES Laboratory of polymer synthesis Laboratory of polymer processing and Surface func onaliza on. Clean Room condi ons Laboratory of physico-chemical characteriza on of biomaterials Mechanical tes ng equipment
  • 22. Novel bioresorbable polymer systems for regenera ve medicine Bioresorbable polymers with thermoplas c elastomer (TPE) behavior are highly valued for several regenera ve medicine applica ons, e. g. car lage, vascular vessels, urology... Polylac de/polylactone copolymers with tuned proper es and no crystalliza on capability are synthesized, characterized and manufactured in different shapes for medical implant applica ons. Polymers may be loaded with biologically ac ve molecules and inorganic nanopar cles (bioglass, hidroxiapa te…) with several biomedical purposes. Universi es of the Basque Country UPV/EHU 2 TRL: 2 Time to market: short/medium/long >5
  • 23. Bioresorbable polymer scaffolds func onalized with a model protein for local delivery of an bio cs and immuno-supresive molecules Polymer scaffolds loaded with an bio c and immunosuppresive molecules are obtained by novel techniques such as electro-spinning and 3D prin ng and ac vated by plasma. A model protein is gra ed through a crosslinker upon the surface. Specific interac ons and miscibility are key issues for controlled delivery profiles. TRL: 2 Time to market: short/medium/long >5 Universi es of the Basque Country UPV/EHU 2
  • 24. Since 2001, the research group from the Pharmacy and Pharmaceu cal Science´s Deparment has been recognized as a University of the Basque Country UPV/ EHU Consolidated group by the Basque Government. The principal inves gator is Dr Jose Luis Pedraz. It is remarkable the implica on in relevant research projects on the field of pharmaceu cal technology, cellular therapy, characteriza on of biomaterials and specially on the development of new sustained and controlled delivery systems for drugs, pep des, proteins, DNA and cells. www.ehu.es/es/web/nanobiocel/home Micro and nano technologies, biomaterials and cells research group. Universi es of the Basque Country UPV/EHU 2
  • 25. NANOMEDICINE RELATED ACTIVITY Microencapsula on of alive cells. Design and op miza on of polymeric systems for immobiliza on of cells with therapeuc c ac vity Micro and nano-par cles as vaccine administra on systems of pep des and proteins Non viral vectors for gene therapy purposes; design and op miza on of non-viral vectors based on lipidic and polymeric nanopar cles Development of modified release formula on based on new polymers to obtain a sustained release profile of drugs Nanocarries for pulmonar administra on:design, op miza on and characteriza on of vehicles in the nanometric range Universi es of the Basque Country UPV/EHU 2 CONTACT PERSON Name: Jose Luis Pedraz E-mail: joseluis.pedraz@ehu.es MAIN INFRASTRUCTURES HPLC with UV-visible; fluorescent and electrochemical detector; HPLC-MS, HPLC-MS/MS; GC- MS; Spray-Dryer; Table ng machine; Par cle size analyzer for liquid suspensions (Coulter, nano-sizer) and solid phase (Helos sympatec); Image acquiring microscope; coa ng pan; single step mixer- granula on-dryer; capsule filler; extruder-spheroniser; dissolu on rate/disintegra on rate determina on equipments; tablet hardness tes ng; Clima c chambers, Jet cu for microcapsules elabora on.
  • 26. Treatment of re na neurodegenera ves diseases through gene therapy using non viral vectors Niosomes represent a recent promising approach for gene delivery purposes. We elaborated a novel niosome formula on based on ca onic lipid, combined with squalene and polysorbate 80 to evaluate the transfec on efficiency in rat re nas. Niosomes prepared by the solvent emulsifica on-evapora on technique were mixed with the pCMSEGFP plasmid to form lipoplexes which were characterized in terms of morphology, size, surface charge, and DNA condensa on, protec on and release. The efficacy of the most promising formula on was evaluated in rat eyes by monitoring the expression of the EGFP a er intravitreal and subre nal injec ons. Lipoplexes successfully transfected HEK-293 and specially ARPE-19 cells, without affec ng the viability. Whereas lipoplexes entered mainly re nal cells by clathrin-mediated endocytosis, HEK-293 cells showed a higher caveolae-dependent entry. A er ocular administra on, the expression of EGFP was detected in different cells of the re na depending on the administra on route. This novel niosome formula on represents a promising approach to deliver gene c material into the re na to treat inherited re nal diseases. TRL 4: technology validated in lab Time to market: medium- 3 a 5 years Universi es of the Basque Country UPV/EHU 2
  • 27. Alzheimer treatment through revasculariza on of cerebral cortex With this development a empts to develop a novel nanotechnology- based strategy to deliver vascular endothelial growth factor (VEGF) to the brain, as a possible therapeu c approach for AD. VEGF-NS were able to improve behavioral deficits, decrease Aβ deposits and promote angiogenesis, as well as reduce neuronal loss and cerebrovascular abnormali es. Furthermore, their ability to protect neuronal cultures against neuroinflamma on induced by LPS provides new insight for future therapeu c approaches in other neurodegenera ve disorders. We also confirmed that encapsulated VEGF secre ng cells also s mulated angiogenesis in the cerebral cortex and hippocampal dentate gyrus. In addi on, we found that VEGF-microcapsule treatment was associated with a depressed expression and ac vity of acetylcholinesterase in the hippocampus of AβPP/PS1 mice, a similar pa ern as first-line medica ons for the treatment of AD. We conclude that stereologically-implanted VEGF- microcapsules exert an acute and long-standing neurotrophic effects, and could be u lized to improve poten al therapies to control the progression of AD. TRL 4: technology validated in lab Time to market: medium- 3 a 5 years Universi es of the Basque Country UPV/EHU 2
  • 28. Health Research Ins tutes 3
  • 29. First health research ins tute in the Basque Country: Created in 2008 Accredited by the ISCIII: indicator of excellence, part of the elite of accredited ins tutes in Spain Unusual ins tute due to its collabora ve (public-private) mul ins tu onal and interdisciplinary structure The core is Donos a University Hospital, and are also incorporated Primary Care, District Hospitals, Public Health, University of the Basque Country UPV/EHU, Technological Centres, Coopera ve Research Centres and private enterprises Health Research Ins tutes 3
  • 30. NANOMEDICINE RELATED ACTIVITY Research on the inmunologic response in the presence of nanopar cles Research on the inmunological response in the presence of nanopar cles Study of apoptosis or necrosis of T lymphocytes incubated with metallic nanopar cles (HINAMOX, NpZn, NpCe, NpTi and NpAl) in a cell growth medium containing fetal serum. CONTACT PERSON Name: Arantza Abad E-mail: arantza.abad@biodonos a.org Health Research Ins tutes 3 TRL: 4 Time to market: long >5
  • 31. Technology Centres 4
  • 32. TECNALIA Research & Innova on is a private, non-profit research organiza on that operates in several markets (Construc on, Energy, Industry, ICT, Transport, Health) and aims at genera ng new bridges between innova on and business. www.tecnalia.com Technology Centres 4
  • 33. NANOMEDICINE RELATED ACTIVITY Synthesis, func onaliza on and characteriza on of polymeric nanopar cles for targeted drug delivery Func onaliza on and characteriza on of carbon-based nanomaterials (graphene, nanotubes) for diagnos cs Design of new 3D-cell-culture-based in vitro assays to study cell-nanopar cle interac ons Toxicological assessment of nanomaterials Technology Centres 4 MAIN INFRASTRUCTURES Clean rooms and laboratories for nanomaterials synthesis and characteriza on Cell culture laboratory Biological test laboratory CONTACT PERSON Name: Fabrice Morin E-mail: fabrice.morin@tecnalia.com
  • 34. New enabling technologies for transdermal delivery of nanopar cles Nanopar cles introduced into the skin may be used for various purposes, from drug delivery to immunomodula on. In par cular, transdermal drug delivery represents one of the most successful and innova ve alterna ves to oral delivery of drugs. The benefits of using transdermal drug delivery include improved systemic bioavailability resul ng from by-passing the first liver metabolism as well as elimina on of the impact of variables due to oral administra on (pH, transit mes, etc.). The use of nanopar cles can further boost the relevance of transdermal drug delivery by, for example, protec ng the delivered ac ve substance from denatura on, adding a sustained release effect, targe ng specific cells, etc. Tecnalia simultaneously develops and characterizes the nanopar cles, nanopar cle release materials and control devices in order to maximize performance. TRL: 3/4 Time to market: long Technology Centres 4
  • 35. Nanotoxicity assessment Nanotoxicology is a science that is s ll in its infancy and there is s ll a major lack of toxicological data for nanopar cles and nanomaterials. It has been demonstrated that the interac ons between nanomaterials and cells are very complex and that conven onal toxicological methods may not be appropriate to assess many of the possible hazards related to these interac ons. The experience of more than 20 years on toxicological evalua on (in vitro and in vivo) of TECNALIA has been applied in the last 8 years to adapt these methodologies to the specific characteris cs and behaviour of nanopar cles. Among others, cell viability, genotoxicity, hemocompa bility, uptake, protein or/and gene expression, oral and dermal toxicity, irrita on, etc. have been analyzed with several types of nanopar cles. Moreover, Tecnalia is commi ed to improving the predic ve capacity of in vitro assays through design of new 3D cell culture models. The aim of this work is to ensure that these assays capture in the most realis c way the nature of the interac ons between cell and nanopar cles that take place in vivo. Time to market: long Technology Centres 4
  • 36. Fundación GAIKER is a organiza on devoted to the development of new technologies from sectors such as Health, Fine Chemistry, Food and Agriculture, among others. From 1985, the Centre has carried out more than 1.100 R+D Projects related to its Knowledge Areas: Biotechnology Plas cs and Composites, Environment and Recycling. www.gaiker.es Technology Centres 4
  • 37. NANOMEDICINE RELATED ACTIVITY In vitro evalua on of the absorp on capa city of nanodrugs ITS for toxicity assessment of nanodrugs MAIN INFRASTRUCTURES Fully equipped in vitro tests laboratory (GLP) Molecular biology laboratory Microscopes laboratory Genomic and proteomic laboratories CONTACT PERSON Name: Oscar Salas E-mail: salas@gaiker.es Technology Centres 4
  • 38. In vitro evalua on of the absorp on capa city of nanodrugs Development of models to simulate physiological barriers in vitro with an aim to es mate the poten al absorp on capacity and toxicological profiles of purpose-designed nanodrugs for the BBB, skin and inhala on routes. TRL: 7 Time to market: short <3 Blood Brain Barrier • Permeability poten al • Transport mechanisms • Neurotoxic profiles • Efficacy Skin • Safety and Efficacy • Inflamma on • Fototoxic poten al • Permeability Inhala on route • Toxicity (inhaled nanodrugs) • Acute, Sub-acute, Subchronic, Chronic, Mul dose • Inflamma on poten al Technology Centres 4
  • 39. ITS for toxicity assessment of nanodrugs An Intelligent Tes ng Strategy has been designed to screen for the toxicity poten al of nanodrugs. TRL: 4 Time to market: medium / 3-5 / Genotoxicidad ROS 2 líneas (+++) (+) (-) E E Citotoxicidad (+++) (+) (-) C 2 líneas 1 líneaB D D Citotoxicidad (+++)(+) (-) A B C C 2 líneas1 línea Technology Centres 4
  • 40. IK4-CIDETEC is a Research Ins tute specialized in genera ng and transferring knowledge and technology in the areas of materials, surfaces and energy. www.cidetec.es Technology Centres 4
  • 41. NANOMEDICINE RELATED ACTIVITY Synthesis of Biomaterials Polymer NPs for theragnosis Nanogels, nanocapsules: pH responsive waterborne colloidal systems for drug-delivery and ssue engineering Injectable hydrogels for ssue engineering Bioac ve surfaces Electrochemical biosensors based on plas c elelctronics Technology Centres 4 MAIN INFRASTRUCTURES 350 m2 classified labs prepared for GMP produc on Chromatography (FPLC, HPLC, GPC) Polymer characteriza on Spectroscopy and microscopy Cell culture CONTACT PERSON Name: Dr. Iraida Loinaz E-mail: iloinaz@cidetec.es
  • 42. TRL: 4 Time to market: medium/long 3-5 / >5 POLYMER NANOPARTICLES FOR TARGETED IMAGING AND THERAPY OF CANCER Mul func onal colloidal systems of nanometric size Single chain polymer nanopar cles of nanometric size (<20nm)produced in water by aesily scalable process for drug delivery and imaging applica ons. IK4-CIDETEC applies this technology for image and treat pancrea c cancer. Technology Centres 4
  • 43. TRL: 4-5 Time to market: short if it is applied as a medical device HYDROGELS Injectable hydrogels with self-healing proper es Owner technology of a new family of injectable hydrogels with astounding self-healing and shear thickening proper es to be used as medical device or injectable scaffold in regenera ve medicine. SEM micrographs of the freeze-dried hydrogel Self-healing process of a hydrogel Technology Centres 4
  • 44. TRL: 4 Time to market: medium NANOCAPSULES Emulsifiers based on amphiphilic diblock copolymers pH responsive capsules based on block copolymers for the encapsula on of Ac ve Pharmaceu cal Ingredients in cosmethics, pharma or food indutry. The length of both diblocks can be adjusted to encapsulate preferen ally hydrophilic or hydrophobic phase. Technology Centres 4
  • 45. IK4-TEKNIKER (TKN) is a private non- profit research organisa on. IK4 Tekniker is part of the IK4 Research Alliance. Micro-Nano manufacturing, Electronics and Smart System ac vi es are closely related in IK4 Tekniker, aiming to integrate the exper se of their main technology areas to support key industrial and service sectors in non-conven onal system development. www.tekniker.es Technology Centres 4
  • 46. Technology Centres 4 NANOMEDICINE RELATED ACTIVITY Micro and Nanofabrica on Unit in a Clean-room In-vitro diagnos c tools for biomolecules and cells detec on by electrochemistry and op cal principles Physical and biochemical modifica on of scaffolds for medicine regenera ve on synthe c and natural biopolymers Coordina on of the FP7 Project NEURIMP (www.neurimp.eu) in the field of regenera ve medicine (2014-2017) MAIN INFRASTRUCTURES Micro and Nanofabrica on by UV-Lithography, Nanoimprin ng, Plasma Etching and Physical Vapour Deposi on Surface Plasmon Resonance, Impedimetric and Voltammetry measurements and own developments based on nanostructures on chip for biomolecules detec on Micro and Nanofluidics. Chips integra on on Smart systems Biofunc onaliza on of biomolecules and cells on substrates or conjuga on with micro/na.par cles CONTACT PERSON Name: Santos Merino E-mail: smerino@tekniker.es
  • 47. Technology Centres 4 TRL: 4 Time to market: short/medium/long <3 / 3-5 / >5 In-vitro diagnos c by LSPR System integra on for microfluidic and sample processing on chip. Mul plexed detec on of biomolecules by Localized Surface Plasmon Resonance (LSPR).
  • 48. Technology Centres 4 TRL: 5 Time to market: short/medium/long <3 / 3-5 / >5 In-vitro diagnos c of biomolecules by electrochemistry measurements Fluidic integra on and sample prepara on on chip for robust and sensi ve detec on of biomolecules.
  • 49. Technology Centres 4 TRL: 5 Time to market: short/medium/long <3 / 3-5 / >5 Micro and Nanostructures for cell a achment, prolifera on and differen a on Physical and Biochemical cues on natural and synthe c biopolymers (PLA, PLGA, PLC, Hyaluronic acid, Condroi n Sulphate, Heparin) through topography and chemical signals induced by ox-Glycosaminoglycans and proteins with control on the microscale. Pherypheral nerve implants containing an internal aligned channels array.
  • 50. Technology Centres 4 Vicomtech-IK4 is a non-profit applied research centre specialised in Computer Graphics, Visual Compu ng and Mul media technologies with 105 employees, 28 of whom are PhD. www.vicomtech.org eHealth & Biomedical Applica on department
  • 51. Technology Centres 4 MAIN INFRASTRUCTURES Vicomtech-IK4 is equipped for research into new medical image display techniques, intraopera ve naviga on, rapid prototyping, etc. The four clinical stages - Diagnosis, Preopera ve, Intraopera ve and Postopera ve - are covered: Equipment: MicroCT, Microscope, US devices, surgical microscope and endoscopes, etc… CONTACT PERSON Name: Grégory Maclair E-mail: gmaclair@vicomtech.org NANOMEDICINE RELATED ACTIVITY Biomedical Image Reconstruc on Biomedical Image Processing, Analysis and Quan fica on Biomedical Mul -Modal Image Registra on Biomedical Image Visualisa on Systems Biology Data Mining, Knowledge Engineering and Visual Analy cs Poten al applica ons: molecular imaging, image-guided drug delivery, in-vitro assay analysis, etc.
  • 52. Technology Centres 4 TRL: 3 Time to market: 3-5 Image processing solu on for nanosystems’s development and valida on Tools for processing and analysis of MRI and SPECT/PET images in combina on with magne c and radiolabelled nanosystems for theranos cs. The designed solu on enables the evalua on of NPs biodistribu on and kine c behavior of the nanosystems developed. PET-based NPs biodistribu on and kine c monitoring for toxicity evalua on MRI-based NPs segmenta on for diagnos c
  • 53. Companies 5
  • 54. Biopraxis Research AIE cons tutes the R&D division of Praxis Pharmaceu cal Group. Praxis is a young pharma company, which focuses in offering novel drugs and diagnosis tools for rare and neglected diseases, combining bio and nano sciences. www.grupo-praxis.com Companies 5
  • 55. NANOMEDICINE RELATED ACTIVITY Nanomedicine is a key pillar for Biopraxis development strategy. We have established a capacita on program supported by the Basque Government, and we have developed an interna onal network of partners to make nanomedicine applied to rare and neglected diseases a reality. A key issue is the-always challenging- industrializa on of this technologies. Companies 5 MAIN INFRASTRUCTURES Equipment for produc on and characteriza on of nano lipid en es Pilot plant for nanovesicles based on compressed fluids (together with Nanomol tech) cGMP produc on lines CONTACT PERSON Name: Angel Del Pozo E-mail: apozo@praxisph.com
  • 56. Novel strategy for the treatment of chronic wounds Lipid nanopar cles are currently receiving increasing interest because they permit the topical administra on of proteins, such as recombinant human epidermal growth factor (rhEGF), in a sustained and effec ve manner. Because chronic wounds have become a major healthcare burden, the topical administra on of rhEGF-loaded lipid nanopar cles, namely solid lipid nanopar cles (SLN) and nanostructured lipid carries (NLC), appears to be an interes ng and suitable strategy for the treatment of chronic wounds. Praxis is has developed this approach in coopera on with University of the Basque Country UPV/EHU, op mizing prototypes and validated their efficacy in vitro and in vivo. Lipid nanopar cles are also applicable to the reformula on of other APIs (i.e. an bio cs or an parasi c). The produc on process has being up scaled in our produc on facili es in Miñano, and will fulfill legal preclinical in the following months. TRL: 5 Time to market: medium 3-5 Companies 5
  • 57. Theranos cs for treatment of glioma In the framework of the FP7 project Theraglio, novel systems for theranos cs for glioma are being developed. These systems are based in the use of microbubbles or micro-vesicles as enhanced contrasts agents, including elements to obtain fluorescence, targe ng of tumor vessels and RMI. The diagnosis elements are further decorated with nanopar cles, in order to give complementary therapeu c proper es as in situ drug delivery systems. TheraGlio will provide mul modal image guidance during surgery with the final goal of prolonging pa ents’ survival, as a result of a safer and larger tumour resec on and tailored delivery of specific chemotherapeu c molecules. The Consor um, composed by ten EU partners will set up a clinical trial for 2017 (More info at www.theraglio.eu). The TheraGlio project is receiving funding from the European Union Seventh Framework Programme (FP7/2007-2013) under Grant Agreement n° 602923”. TRL: 6 Time to market: medium 3-5 Companies 5
  • 58. Innova ve drugs based on nano en es produced by compressed fluids This technology, developed by ICMAb-CSIC/ Nanomol and GMP up scaled by Praxis is based on the use of compressed fluids (CFs), mainly CO2 , as green solvents for the prepara on, in a single unit opera on, of nanopharmaceu cals. These nanopar culate materials are obtained with outstanding control of their structural characteris cs (size, polymorphic purity, crystallinity level, morphology, supramolecular assembly). This technology has already shown its wellness for the produc on of innova ve mul func onal NVs for drug delivery and yielded nanomedicine candidates, which are in advanced stage of pre-clinical development and with promising perspec ves to proceed to clinical tes ng. Nano vesicles are easy to conjugate with targe ng molecules, meaning an interes ng pla orm for drug reposi oning for different applica ons (Rare lysosomal deposit diseases like Fabry and Sanfilippo, novel an microbials, an cancer drugs, etc. TRL: 5 Time to market: medium 3-5 Companies 5
  • 59. Midatech is a world leader in the design, synthesis and manufacture of biocompa ble gold nanopar cles with a core focus on therapeu cs for diabetes and cancer. The Company is also exploring the use of GNPs in other healthcare applica ons including vaccines, diagnos cs and medical imaging. www.midatechgroup.com Companies 5
  • 60. NANOMEDICINE RELATED ACTIVITY Novel par cles with single or mul ple ac ve pharmaceu cal ingredients tailored to op mal therapeu c benefits Seasoned management to guide development of therapeu cs from bench top to bedside Advancing drug pipeline: successful phase I safety and drug proper es demonstrated Companies 5 MAIN INFRASTRUCTURES State-of-the-art manufacturing facility with sufficient capacity for manufacturing clinical trial materials Separate sterile produc on unit within its GMP manufacturing facility CONTACT PERSON Name: Jus n Barry E-mail: barry@midatech.eu
  • 61. METABOLIC DISEASE: DIABETES Transbuccal insulin Midatech’s most advanced programme takes advantage of the fact that binding a pep de hormone to a nanopar cle allows its absorp on across the mucosa of the cheek. This has enabled Midatech and its partner, Monosol Rx, to develop needle-free delivery of insulin for diabetes mellitus. As part of this joint venture, Midatech has combined its unique GNP technology with its partner’s exper se in transi oning pharmaceu cals to film to develop a self- dissolving strip containing nanopar cle insulin referred to as Midaform™ Insulin PharmFilm®. This mode of administra on provides a more convenient and discrete form of insulin delivery than injec ons and has the poten al to make injec ons redundant in the treatment of diabetes. TRL: a Phase II trial is planned to start in 2015 Time to market: medium 3-5 Companies 5
  • 62. ONCOLOGY Midatech is developing a new cancer therapies based on nanomedicines combining validated chemotherapeu cs, targe ng molecules and gold NPs. Ovarian Cancer: Development of GNPs which carry a tumour-targe ng agent, folic acid (FA) and a pla num cytotoxic compound. The targe ng agent has been selected because ovarian carcinoma cells over-express the receptor for FA on their membranes and pla num is an effec ve cytotoxic for ovarian cancer. Liver Cancer: Chemotherapeu cs will be a ached to liver- targe ng GNPs and tested for effec veness in liver cancer models. A range of chemotherapeu cs are being studied. Brain Cancer: The Company has demonstrated the specific migra on of GNPs to the brain. Op miza on of the passage of GNPs through the blood-brain-barrier combined with chemotherapeu c agents will allow a new genera on of therapeu c op ons for diseases such as glioblastomas. TRL: pre-clinical stage of development Time to market: long >5 Companies 5
  • 63. www.nanobasque.eu nanobasque@spri.es nanoBasque EKONOMIAREN GARAPEN ETA LEHIAKORTASUN SAILA DEPARTAMENTO DE DESARROLLO ECONÓMICO Y COMPETITIVIDAD

Related Documents